Retatrutide's phase 2 heart-rate signal and how to think about it

On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion.

Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it.

retatrutide, monoisotopic mass near 4731.3 Da, 14 weeks of my own notes, and 6 lots from 2 suppliers with a purity figure on each. That is the whole basis of what follows.

What I want checked is the reasoning I have built on top of it, not the figures themselves.

Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes.

Genuinely open to being wrong about this one.

This follows post #2 rather than contradicting it.

Discontinuation for adverse effects in phase 2 was not negligible at the higher doses. That figure belongs next to the efficacy figure whenever the efficacy figure is quoted.

The part I am sure of is shorter than the part I have written.

Worth separating two things that the opening post runs together.

Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.

Confirming post #2 from a second method, which matters more than confirming it from a second person.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

Duration is the other limitation. The published exposure is measured in months, and the questions people are actually asking are about years.

The strength of my opinion here exceeds the strength of my evidence.

On post #4 — agreed on the reasoning, with one qualification.

Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.

The number is defensible. The precision I gave it is not.

Post #6 is the version of this I will quote in future. One addition.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

Nothing above should be read as advice about what anyone else should do.

Where I part company with post #8, and it is a narrow parting.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

The disagreement above is smaller than it looks once the terms are fixed.

Worth separating two things that post #7 runs together.

The phase 2 obesity data is genuinely striking and it is phase 2 data. Sample sizes at that stage characterise a dose-response relationship; they do not characterise a safety profile, and treating them as though they did is the error to avoid here.

Adding the caveat now so it does not have to be extracted later.

Useful. I had the fact and not the reason, which turns out to be the important half.

The phase 3 programme is ongoing and its results will change what can be said here. Until then, this subcategory's convention is to state the phase alongside any result quoted.

A weak preference rather than a position.

Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.

Noting that I have skin in this question and have tried to discount for it.